We Need More Transparency on the Cost of Specialty Drugs
Harvard Business Review
NOVEMBER 4, 2014
In a July 2014 JAMA article , Troyen Brennan and William Shrank, respectively the chief medical and scientific officers at CVS Caremark, a major pharmacy benefit manager (PBM), estimated that with as many as 3 million eligible HCV patients in the U.S., In one analysis , Gordon D. Health Innovation'
Let's personalize your content